UK develops new tool to prevent heroin deaths

Published at 4:17 p.m. on August 7, 2014 | Modified at 4:29 p.m. on August 7, 2014

University of Kentucky pharmacy professor Daniel Wermeling saw an unmet medical need—a better way to fight opioid overdose. Wermeling's company, AntiOp Inc., developed a naloxone nasal spray that has received more than $5 million in funding and Fast Track designation from the FDA. AntiOp is partnering with Reckitt Benckiser Pharmaceuticals Inc. to complete the development and launch the product commercially. Produced by Research Communications at the University of Kentucky. (University of Kentucky)

Lexington Herald-Leader is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service